Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$11.66 USD
+0.41 (3.64%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $11.78 +0.12 (1.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
STOK 11.66 +0.41(3.64%)
Will STOK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STOK
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Other News for STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics appoints Jason Hoitt as Chief Commercial Officer
Buy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioning
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Haleon PLC (GB:HLN) and Stoke Therapeutics (STOK)
12 Health Care Stocks Moving In Friday's After-Market Session